Browse

Efficacy and safety of oral SK3530 for the treatment of erectile dysfunction in Korean men: a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group clinical trial

Cited 20 time in Web of Science Cited 18 time in Scopus
Authors
Paick, Jae-Seung; Choi, Hyung-Ki; Kim, Sae-Chul; Ahn, Tai-Young; Kim, Je-Jong; Park, Jong-Kwan; Park, Kwang-Sung; Lee, Sung-Won; Kim, Sae-Woong; Park, Kwanjin; Jung, Hyonggi; Park, Nam-Cheol
Issue Date
2008-07-23
Publisher
Wiley-Blackwell
Citation
Asian J Androl. 2008; 10(5): 791-798
Keywords
Double-Blind MethodErectile Dysfunction/*drug therapyHumansKoreaMaleMiddle AgedPatient SatisfactionPhosphodiesterase Inhibitors/*administration & dosage/adverse effectsPlacebosPyrimidinones/*administration & dosage/adverse effectsSulfones/*administration & dosage/adverse effectsTreatment Outcome
Abstract
AIM: To evaluate the efficacy and safety of SK3530, a newly developed type 5 phosphodiesterase inhibitor (PDE5I), in Korean men with erectile dysfunction (ED). METHODS: A total of 119 patients were randomized at 10 centers in Korea to receive either SK3530 (50, 100, or 150 mg; n = 89) or placebo (n = 30) taken l h before anticipated sexual activity for an 8-week period. The patients were evaluated at baseline and 4 and 8 weeks after beginning therapy. Efficacy was assessed using the International Index of Erectile Function (IIEF), Sexual Encounter Profile (SEP), and the Global Assessment Question (GAQ). Safety was analyzed by adverse events, laboratory values and vital signs. RESULTS: At the end of the study, all the primary and secondary efficacy end-points were statistically significantly improved by SK3530 compared with placebo (P<0.05). Of the 89 patients in the treatment arm, 36 (42.3%) achieved normal erectile function after treatment, including six patients with severe ED. Treatment-related adverse events occurred in 32 patients. The most common adverse events were flushing, headache, dizziness and eye redness (10.9%, 7.6%, 2.5% and 2.5%, respectively), and most were mild. Only two patients discontinued treatment during the study period because of adverse events. CONCLUSION: The results of our phase II study have confirmed the efficacy and safety of SK3530 in a broad population of men with ED of various etiologies and severity. The optimal doses in terms of efficacy and safety were determined to be 50 mg and 100 mg, respectively.
ISSN
1008-682X (Print)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18645683

http://www.nature.com/aja/journal/v10/n5/pdf/aja2008100a.pdf

http://hdl.handle.net/10371/68098
DOI
https://doi.org/10.1111/j.1745-7262.2008.00422.x
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Urology (비뇨기과학전공)Journal Papers (저널논문_비뇨기과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse